EDIT vs. ALEC, FDMT, NVAX, HLVX, ITOS, AMAM, MESO, AUTL, VYGR, and AGEN
Should you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Alector (ALEC), 4D Molecular Therapeutics (FDMT), Novavax (NVAX), HilleVax (HLVX), iTeos Therapeutics (ITOS), Ambrx Biopharma (AMAM), Mesoblast (MESO), Autolus Therapeutics (AUTL), Voyager Therapeutics (VYGR), and Agenus (AGEN). These companies are all part of the "biological products, except diagnostic" industry.
Editas Medicine vs.
Alector (NASDAQ:ALEC) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, community ranking, valuation, risk and analyst recommendations.
Alector has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500.
In the previous week, Alector had 1 more articles in the media than Editas Medicine. MarketBeat recorded 4 mentions for Alector and 3 mentions for Editas Medicine. Alector's average media sentiment score of 0.71 beat Editas Medicine's score of 0.67 indicating that Alector is being referred to more favorably in the media.
Editas Medicine received 156 more outperform votes than Alector when rated by MarketBeat users. However, 60.26% of users gave Alector an outperform vote while only 54.85% of users gave Editas Medicine an outperform vote.
Alector currently has a consensus price target of $16.43, suggesting a potential upside of 140.54%. Editas Medicine has a consensus price target of $15.86, suggesting a potential upside of 66.04%. Given Alector's stronger consensus rating and higher probable upside, research analysts plainly believe Alector is more favorable than Editas Medicine.
Alector has higher revenue and earnings than Editas Medicine. Alector is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.
Alector has a net margin of -107.05% compared to Editas Medicine's net margin of -960.70%. Editas Medicine's return on equity of -56.20% beat Alector's return on equity.
65.0% of Alector shares are held by institutional investors. Comparatively, 69.7% of Editas Medicine shares are held by institutional investors. 12.9% of Alector shares are held by company insiders. Comparatively, 2.2% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Alector beats Editas Medicine on 11 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Editas Medicine Competitors List
Related Companies and Tools
